#United States #Philadelphia #Cell Therapy #Minaris #viral vectors

Minaris Transforms Business Structure

In an exciting development within the biotechnology industry, Minaris, a prominent player in the cell and gene therapy (CGT) contract development and manufacturing organization (CDMO), has announced the establishment of a dedicated Viral Vectors business unit. This strategic evolution reflects Minaris' commitment to addressing the changing demands in the therapy market and enhancing its service offerings by organizing its operations around three specialized areas: Cell Therapies, Viral Vectors, and Advanced Testing.

A Focus on Evolving Customer Needs

The creation of the Viral Vectors business unit marks a significant shift in Minaris’ operational strategy. As explained by Orla Cloak, CEO of Minaris, the modified business model aims to meet the emerging needs of clients while keeping pace with market trends. By concentrating on Viral Vectors, Minaris seeks to refine expertise in a domain increasingly critical for developers engaged in cell and gene therapies.

Each of the three business units - Cell Therapies, Viral Vectors, and Advanced Testing - will function under experienced leadership to integrate specialized capabilities. For instance, Dr. Luciana Mansolelli will lead the Cell Therapies unit, while Dr. Eytan Abraham takes charge of the new Viral Vectors division. Dr. Ilya Koltover will oversee Advanced Testing services. This structure promises a coordinated experience for customers, ensuring consistency across development, manufacturing, quality assurance, and testing.

Comprehensive Services Across Business Units

Minaris Cell Therapies operates with over 25 years of experience in the field, focusing on both autologous and allogeneic programs. The Cell Therapies team is adept at facilitating clients from the initial stages of development through clinical trials and commercial manufacturing. They specialize in processes such as technology transfer, GMP-compliant manufacturing practices, quality systems, and scalable strategies.

The new Viral Vectors unit will primarily support technologies integral to gene therapy and genetically modified cell therapy initiatives. The team, combining more than a decade of experience, specializes in viral vector production and analytical development, ensuring that clients benefit from expertise in manufacturing scalable production and high-quality vectors. Centralized in Philadelphia, this division capitalizes on the strong technological portfolio established in collaboration with OXGENE in the UK.

Minaris Advanced Testing round out the operation with a robust suite of services related to GMP biosafety, potency assays, and comprehensive analytical testing. This unit brings forth an impressive 40 years of experience designed to give clients confidence and clarity in navigating regulatory landscapes during development and commercialization.

Enhanced Customer Engagement and Efficiency

The evolving structure is not merely about expanding capabilities; it’s also about enhancing customer engagement. By permitting clients to interact with one business unit or multiple units depending on their program needs, Minaris adds a layer of flexibility that is crucial for today’s intricate therapeutic landscape. The comprehensive service offerings ensure that customers can move efficiently from the research stage through to market entry, particularly as the industry collectively shifts towards in vivo gene therapies that call for advanced vector development and stringent quality guidelines.

Moreover, the establishment of this dedicated business unit will facilitate expedited decision-making processes, which is particularly pertinent given the rapid pace of innovation in CGT. The need for robust and reliable viral vector solutions is becoming more prominent as programs advance from conception into clinical application. With this strategic realignment, Minaris aims to provide unparalleled support throughout this critical development pathway.

Future Directions

This realignment in Minaris' operational model, effective from October 1, 2026, signifies their commitment to remaining at the forefront of the biotech industry as it evolves. Following the impactful acquisitions in 2025, Minaris is now strategically poised to build upon its established heritage in therapy manufacturing and testing. The collaborative approach that defines Minaris’ operations drives their mission to support innovators in advancing complex therapies, ultimately benefiting patients globally.

As the demand for enhanced therapeutic solutions continues to grow, Minaris is redefining how it serves its partners, ensuring a commitment to quality, scientific innovation, and therapeutic advancement.

For further details, please visit Minaris’ official website or connect with them on LinkedIn.